Scientists dive deep into HIV immune cells to unlock secrets of early treatment

NCT ID NCT00039689

Recruiting now Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 8 times

Summary

This study collects white blood cells from HIV patients through a process called leukapheresis to examine how the immune system responds to early treatment. Researchers aim to enroll 60 adults—30 with early HIV and 30 with chronic HIV—who are not yet on antiretroviral therapy. Participants will provide blood samples before starting treatment and three times a year afterward, helping scientists understand immune function and viral suppression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could reveal how early HIV treatment preserves immune function, pointing toward better treatment strategies.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to direct patient benefits, and results may not apply to all HIV patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.